Published in Gene Therapy Weekly, January 9th, 2003
Ganciclovir is a standard adjuvant to herpes simplex virus thymidine kinase (HSV-tk) gene therapy. Medical collaborators at Osaka University Medical School in Japan and the University of Sao Paulo Medical School in Brazil have reported that silicone-mixed ganciclovir pellets (GCV-pellet) extend survival in rodents bearing human gliosarcoma.
The researchers compared rodents treated with HSV-tk gene therapy and tumor-implanted GCV-pellet with other rodents treated with HSV-tk...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.